AFM
CLDX icon

Anson Funds Management’s Celldex Therapeutics CLDX Stock Holding History

Anson Funds Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-81,990
Closed -$243K – 33
2018
Q4 		$243K Buy
+81,990
New +$403K 0.14% 38

Other funds holding CLDX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Anson Funds Management's CLDX Position: Q1 2019 in Review

Anson Funds Management sold out of Celldex Therapeutics (CLDX) in Q1 2019, closing a stake of 81,990 shares — an estimated $243K sold.

Anson Funds Management first reported a position in CLDX in Q4 2018 and held it in 1 quarter. The position peaked at $243K in Q4 2018. 53 funds tracked by Wall St. Rank hold CLDX as of Q1 2019.

  • Anson Funds Management reported no remaining Celldex Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Anson Funds Management sold 81,990 Celldex Therapeutics shares in Q1 2019, an estimated $243K.
  • Anson Funds Management first reported a position in Celldex Therapeutics in Q4 2018 and held it in 1 quarter.
  • Anson Funds Management's Celldex Therapeutics position peaked at $243K in Q4 2018.
  • 53 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2019.

Based on Anson Funds Management's 13F filing for Q1 2019, filed 15 May 2019.